Nicotine therapeutic benefits: Difference between revisions

Line 1,128:

='''Seizures / Epilepsy'''=

===2021 [https://pubmed.ncbi.nlm.nih.gov/34763266/ Precision treatment with nicotine in autosomal dominant sleep-related hypermotor epilepsy (ADSHE): An observational study of clinical outcome and serum cotinine levels in 17 patients]===

*This is the hitherto largest observational study supporting a favorable effect of nicotine in this specific seizure disorder. Better seizure control from transdermal nicotine compared to only day-time consumption suggests benefit from exposure throughout the night. According to current clinical experience, patients with uncontrolled ADSHE harboring relevant mutations should be offered precision treatment with transdermal nicotine.

Line 1,140:

Line 1,141:

*"Four patients were prescribed nicotine patches for intractable seizures. Three of 4 patients had a clinical response, with >50% seizure reduction."

*"Conclusions: Treatment with a nicotine patch can be an effective therapy in epilepsy patients with nAChR gene variants."

*Citation: Fox J, Thodeson DM, Dolce AM. Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants. J Child Neurol. 2021 Apr;36(5):371-377. doi: 10.1177/0883073820974851. Epub 2020 Dec 7. PMID: 33284031

===2020 [https://pubmed.ncbi.nlm.nih.gov/32097883/ Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy]===

Line 1,149:

Line 1,151:

*[https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1528-1167.2012.03715.x PDF Version]

*Citation: Zerem, A., Nishri, D., Yosef, Y., Blumkin, L., Lev, D., Leshinsky‐Silver, E., Kivity, S. and Lerman‐Sagie, T. (2013), Resolution of epileptic encephalopathy following treatment with transdermal nicotine. Epilepsia, 54: e13-e15. doi: 10.1111/j.1528-1167.2012.03715.x

*Acknowledgments: We thank Dr. Marcio Sotero De Menezes for suggesting the nicotine patch treatment in our patient following resolution of epilepsy in his patient with a similar presentation.

*Key Words: Autosomal dominant nocturnal frontal lobe epilepsy, Nicotinic acetylcholine receptors, Refractory epilepsy.

===2003 [https://onlinelibrary.wiley.com/doi/full/10.1046/j.1528-1157.2003.58102.x-i1?sid=nlm%3Apubmed Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study]===

Line 1,156:

*[https://sci-hub.st/https://doi.org/10.1046/j.1528-1157.2003.58102.x-i1 PDF Version]

*Citation: Willoughby, J.O., Pope, K.J. and Eaton, V. (2003), Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study. Epilepsia, 44: 1238-1240. doi: 10.1046/j.1528-1157.2003.58102.x-i1

*Acknowledgments: The Pharmacy Department undertook randomization and allocation of the trial phase. Nicotine patches and matching placebo patches were provided through SmithKlineBeecham Consumer Healthcare Australia. The patient was cooperatively conscientious in her documentation of seizures. Dr. Stephen Johnson provided helpful comments on nicotinic receptor pharmacology.

<br>

@@ Line 1,128: / Line 1,128: @@
 ='''Seizures / Epilepsy'''=
 ===2021 [https://pubmed.ncbi.nlm.nih.gov/34763266/ Precision treatment with nicotine in autosomal dominant sleep-related hypermotor epilepsy (ADSHE): An observational study of clinical outcome and serum cotinine levels in 17 patients]===
 *This is the hitherto largest observational study supporting a favorable effect of nicotine in this specific seizure disorder. Better seizure control from transdermal nicotine compared to only day-time consumption suggests benefit from exposure throughout the night. According to current clinical experience, patients with uncontrolled ADSHE harboring relevant mutations should be offered precision treatment with transdermal nicotine.
@@ Line 1,140: / Line 1,141: @@
 *"Four patients were prescribed nicotine patches for intractable seizures. Three of 4 patients had a clinical response, with >50% seizure reduction."
 *"Conclusions: Treatment with a nicotine patch can be an effective therapy in epilepsy patients with nAChR gene variants."
+*Citation: Fox J, Thodeson DM, Dolce AM. Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants. J Child Neurol. 2021 Apr;36(5):371-377. doi: 10.1177/0883073820974851. Epub 2020 Dec 7. PMID: 33284031
 ===2020 [https://pubmed.ncbi.nlm.nih.gov/32097883/  Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy]===
@@ Line 1,149: / Line 1,151: @@
 *[https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1528-1167.2012.03715.x PDF Version]
 *Citation: Zerem, A., Nishri, D., Yosef, Y., Blumkin, L., Lev, D., Leshinsky‐Silver, E., Kivity, S. and Lerman‐Sagie, T. (2013), Resolution of epileptic encephalopathy following treatment with transdermal nicotine. Epilepsia, 54: e13-e15. doi: 10.1111/j.1528-1167.2012.03715.x
-*Acknowledgments: We thank Dr. Marcio Sotero De Menezes for suggesting the nicotine patch treatment in our patient following resolution of epilepsy in his patient with a similar presentation.
-*Key Words: Autosomal dominant nocturnal frontal lobe epilepsy, Nicotinic acetylcholine receptors, Refractory epilepsy.
 ===2003 [https://onlinelibrary.wiley.com/doi/full/10.1046/j.1528-1157.2003.58102.x-i1?sid=nlm%3Apubmed Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study]===
@@ Line 1,156: / Line 1,156: @@
 *[https://sci-hub.st/https://doi.org/10.1046/j.1528-1157.2003.58102.x-i1 PDF Version]
 *Citation: Willoughby, J.O., Pope, K.J. and Eaton, V. (2003), Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study. Epilepsia, 44: 1238-1240. doi: 10.1046/j.1528-1157.2003.58102.x-i1
-*Acknowledgments: The Pharmacy Department undertook randomization and allocation of the trial phase. Nicotine patches and matching placebo patches were provided through SmithKlineBeecham Consumer Healthcare Australia. The patient was cooperatively conscientious in her documentation of seizures. Dr. Stephen Johnson provided helpful comments on nicotinic receptor pharmacology.
 <br>